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Clinical indications of premenstrual
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Qian Yang1*, Arvid Sjölander1, Yuchen Li1, Alexander Viktorin1, Elizabeth R. Bertone-Johnson2,3, Weimin Ye1,
Fang Fang4, Unnur A. Valdimarsdóttir1,5,6† and Donghao Lu4,6†

Abstract
Background: Premenstrual disorders, including premenstrual syndrome and premenstrual dysphoric disorder, are
suggested to be correlated with suicidal behavior and accidents in cross-sectional and retrospective studies.
However, prospective data are still lacking.
Methods: We performed a population-based cohort study including 1,472,379 Swedish women of reproductive age
who were followed from 2001 to 2012. Within the cohort, we also performed a sibling analysis where we
compared the rates of injury between full sisters. By linking to the Patient and the Prescribed Drug Registers, we
identified 18,628 women with any clinical indications for premenstrual disorders in the cohort (population analysis)
and 7674 women in the sibling analysis. Any injury, primarily suicidal behavior (completed suicide and suicide
attempt) or accidents (e.g., fall and transportation accidents), was identified through the Patient and Causes of
Death Registers as the primary outcome. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) of
these outcomes among women with premenstrual disorders in both population and sibling analyses using
multivariable Cox proportional hazards regression.
Results: During a maximal follow-up of 12 years (mean 9.55 years), we identified 2390 women with premenstrual
disorders with any injury; 216 through suicidal behavior and 2191 through accidents. Compared to women without
premenstrual disorders, women with premenstrual disorders were at increased risk of any injury (HR 1.37, 95% CI
1.31–1.42), particularly suicidal behavior (HR 2.26, 95% CI 1.97–2.59) and accidents (HR 1.32, 95% CI 1.27–1.38). Such
associations somewhat attenuated yet remained significant in the sibling analysis (HRs: 1.31 for any injury, 1.86 for
suicidal behavior, and 1.29 for accidents). Additional adjustment for psychiatric comorbidities minimally altered the
associations with any injury and accidents in both population and sibling analyses, whereas the association with
suicidal behavior was considerably attenuated to non-significance in the sibling analysis. Such risks were particularly
strong within 2 years after receiving the diagnosis of premenstrual disorders and were evident among women with
premenstrual disorders with and without psychiatric comorbidities.
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Conclusions: Our findings suggest that women with a clinical indication of premenstrual disorders are at increased
subsequent risk of injury, particularly accidents within the first 2 years after diagnosis.
Keywords: Premenstrual disorders, Injury, Suicidal behavior, Accidents, Cohort study

Background
Premenstrual disorders (PMD), characterized by affective
and physical symptoms that cyclically occur 7–10 days
before menstruation, affect millions of women of reproductive age worldwide. PMD include premenstrual syndrome (PMS) and premenstrual dysphoric disorder
(PMDD). The former is defined by the American College
of Obstetricians and Gynecologists (ACOG) [1], and the
latter is an official diagnosis in the Diagnostic and Statistical Manual of Mental Disorders (DSM), characterized
by pronounced affective symptoms [2, 3]. Both PMS and
PMDD are associated with social impairment, which is
often more substantial among patients with PMDD [2].
The estimated prevalence is 20 to 40% for PMS and 2 to
6% for PMDD [2, 4–7]. The chronic and cyclic condition
may have a lasting impact on women’s quality of life [8].
Indeed, the level of impairment attributable to PMD has
been suggested to be not much lower than in major depression [9]. Despite clear evidence for decreased physical and mental well-being among women with PMD
[10], little is known about the impact on major health
outcomes, such as injury, in this population.
Injury is a major public health concern among women
of reproductive age. Intentional and unintentional injuries together account for approximately 15% of deaths in
women aged 15–49 years in global studies [11]. It is
however unclear to what extent injury is associated with
PMD. PMD have been hypothesized to increase risk of
suicide behavior, given the severity of cyclic depressive
and anxiety symptoms associated with these conditions.
Indeed, the results from a systematic review including
10 retrospective studies suggest that PMD were associated with suicide attempts [12]. This association was independent of psychiatric comorbidities for PMDD but
not for PMS [13]. Furthermore, it is plausible that
women with PMD are more prone to accidents due to
the fatigue, irritability, and lack of concentration during
the days before menstruation. In a cross-sectional study,
PMD was associated with accidents, particularly during
the days preceding and during menstruation [14]. Another retrospective study among female soccer players
indicates a positive correlation between premenstrual
symptoms and accidents [15]. However, these studies
were conducted in relatively small and distinct populations, and mostly rely on retrospective assessments of
premenstrual symptoms and/or injury, which may be
prone to recall bias. Moreover, PMD and suicidal

behavior have been reported to cluster within families
[16, 17]. Because socioeconomic disadvantage and genetic susceptibility may confound the reported associations [16, 18, 19], prospective data combined with
sibling analyses are needed to estimate the association of
PMD and risk of injury. We assessed these relations in a
Swedish population-based cohort, comparing the risk of
injury in women with clinical indications of PMD to risk
in the general population and in their full sisters.

Methods
Study design

We conducted a registry-based cohort study of 1,543,
653 women who were born in Sweden from 1960 to
1990 and resided in Sweden in 1990, according to the
Swedish Population and Housing Census. Using the
unique personal identification numbers assigned to every
resident, we cross-linked all women to the nationwide
Causes of Death Register and Migration Register. All
women were followed from January 1, 2001, or their 15
birthday (as 96% Swedish women would have had menarche by age 15 [20]), whichever occurred last, until
death, emigration, bilateral oophorectomy, or hysterectomy, their 52nd birthday (the average age of menopause
in Sweden [21]), or December 31, 2012, whichever occurred first. We excluded 71,346 women due to bilateral
oophorectomy or hysterectomy (n=2698), emigration
(n=64,689), or death (n=3,959) before cohort entry, leaving 1,472,379 women in the cohort (population analysis).
The Swedish Multi-Generation Register consists of information on 97% of mothers and 95% of fathers of individuals born after 1932 and alive in 1961 [22]. By linking
to the register, we identified 638,910 women who were
full sisters (i.e., sharing the same biological parents) for
the sibling analysis.
Ascertainment of premenstrual disorders

Clinical indications of PMD were identified using any
primary or secondary clinical diagnosis of PMD from
the Patient Register (625E in International Classification
of Diseases (ICD) 9th revision (ICD-9) and N943 in
ICD-10). The Patient Register has nationwide coverage
on inpatient care from 1987 onward and includes information on more than 80% of specialist-based outpatient
visits from 2001 onward with high validity (positive predicted value of 85–95% across diseases) [23]. All PMD
diagnoses obtained from the Patient Register are
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considered provisional, as we could not confirm that all
providers of PMD diagnoses ascertained from the Patient Register used two cycles of prospective daily symptom ratings for diagnosing [3], although it is required in
the Swedish healthcare guidelines for PMDD in many
regions [24]. The Patient Register does not cover diagnoses made in primary care, and 49.3% of mental health
conditions are treated in primary care in Sweden [9].
Therefore, we also identified PMD by searching the Prescribed Drug Register for any PMD diagnosis or clear indication of PMD treatment in prescriptions of antidepressants (the Anatomical Therapeutic Chemical
(ATC) code: N06AB, N06AX, N06AA) and oral contraceptives (ATC code: G03A, G02B). We included only
prescriptions explicitly made for PMD treatment, as indicated by PMD diagnosis/prescription specific to PMD.
Diagnostic codes and keywords indicated in prescriptions are described in supplementary Table S1. The
register collects information on drugs redeemed with a
prescription from all pharmacies in Sweden from July
2005 onward, including drugs prescribed in primary care
[25]. We defined the date of PMD diagnosis as either
the date of clinical diagnosis or the date that a prescription for PMD medication was filled, whichever came
first.
PMD were treated as a time-varying exposure. Women
who had not received a diagnosis of PMD during followup contributed person-time to the reference group.
Women with PMD contributed person-time to the reference group from the start of follow-up until the date of
diagnosis and contributed to the PMD group thereafter.
Ascertainment of injury

By linking to the Patient Register and the Causes of
Death Register, we identified the first injury resulting in
healthcare visit (either as the primary or secondary diagnosis) or death (either as underlying or contributory
cause) experienced by participants during follow-up. We
also identified first injury event due to suicidal behavior
(i.e., completed suicide and suicide attempt), accidents,
assaults, and undetermined injury, where available information was insufficient to make a distinction between
the aforementioned three subtypes, separately. Given
our a priori hypotheses, we primarily focused on suicidal
behavior and accidents in our main analysis. We further
sub-grouped accidents into (1) falls, (2) transportation
and accidents by other external factors, (3) accidents by
natural forces or contact with animals or plants, (4) cutting or piercing, (5) poisoning, and (6) others (supplementary Table S1). Injuries that occurred before the
start of the follow-up were defined as “history of injury”
and not treated as outcomes; only the first injury occurring during the follow-up was registered as an outcome
event.
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The Patient Register covers >90% of hospital discharges nationwide for injury since 1987 and has a high
validity (94.8%) for diagnosing injury [23]. Ascertainment of injury-related deaths in the Causes of Death
Register is considered highly accurate [26] and complete
[27].
Covariates

Information about year of birth and region of residence
was obtained from the Swedish Population and Housing
Census in 1990, while information on the highest educational level was retrieved from the Swedish Education
Register, which is updated through 2001. Comorbid psychiatric diagnoses were identified from the Patient Register from 1981 onward. PMD are commonly comorbid
with psychiatric disorders, which may both mediate and
confound the association between PMD and injury. We
therefore defined psychiatric comorbidities for all
women by identifying any diagnosis of psychiatric disorders (290-319 in ICD-8/9, F10-F90 in ICD-10) throughout follow-up from the Patient Register. Psychiatric
comorbidities were then treated as a time-varying
covariate.
Statistical analysis

First, we compared the distributions of demographic
characteristics between the reference and PMD groups
in both the population analysis and the sibling analysis.
The characteristics of PMD patients identified via clinical diagnosis and through treatment indication were
evaluated separately. Next, we calculated unadjusted incidence rates (number of events divided by accumulated
person-years) of injury in both groups, separately.
In the population analysis, we used Cox proportional
hazards regression (attained age as the underlying timescale) to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of injury among women with PMD,
compared to the reference group. We accounted for the
relatedness of individuals (i.e., sisters) using robust sandwich estimator of variance in the population analysis
[28]. The proportional hazard (PH) assumption was
tested by plotting the Schoenfeld residuals. Additionally,
we conducted a sibling analysis using stratified Cox proportional hazards regression. The sibling analysis contrasts the rates within each set of full sister discordant
on PMD diagnosis and inherently controls for unmeasured factors (e.g., shared genetic and familial environmental factors) shared between sisters [29].
We performed separate analyses for the 4 types of injury: (1) suicidal behavior, (2) accidents, (3) assaults, and
(4) undetermined injury. We further conducted an analysis of accident subtypes.
We conducted a series of sensitivity analyses to assess
the robustness of the PMD classification and assess the
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potential impact of misclassification. To assess potential
differences in outcomes among PMD patients by diagnosis type, we differentiated between PMD identified by (1)
clinical diagnosis, (2) treatment indication, and (3) clinical diagnosis and treatment indication. Although all
diagnoses in the Patient Register are made by specialists
with high validity [23], the clinical diagnosis of PMD has
not been validated. To further test the validity of PMD
diagnoses, we restricted the PMD group to patients with
at least two consecutive PMD diagnoses appearing at
least 28 days apart in the Patient Register. We also conducted a simulation analysis and calculated hazard ratios
for injury in testing conditions where 10–80% of PMD
diagnoses were false positives [30]. Finally, because use
of antidepressants or hormonal contraceptives may be
associated with different risk of suicidal behavior [31,
32], a sensitivity analysis was conducted by restricting
our primary analysis to untreated PMD.

Page 4 of 12

In all analyses, attained age was used as the underlying
timescale. We adjusted for calendar year of birth, educational level, region of residence, and history of injury in
Model 1. Psychiatric comorbidities were additionally adjusted for in a time-varying manner in Model 2. However, we only employed Model 2 for the analyses
subsequent to the primary analysis, whenever applicable.
All covariates were categorized (Table 1).
Because PMD has been associated with multiple psychiatric comorbidities [33], we repeated our primary
analysis by separately adjusting for the number of psychiatric comorbidities and individual type of psychiatric
comorbidities (e.g., substance abuse, schizophasia) in a
time-varying way. Finally, as previous suicidal behavior
is a strong predictor of suicidal behavior [34], we additionally adjusted for history of suicidal behavior when
assessing the association between PMD and suicidal
behavior.

Table 1 Characteristics of women with and without premenstrual disorders (PMD)
Sibling cohort a

Population cohort
Reference N (%)

PMD N (%)

Reference N (%)

PMD N (%)

1,472,310

18,628

631,236

7,674

1960–1964

239,959 (16.3)

4346 (23.3)

80,813 (12.8)

1471 (19.2)

1965–1970

255,554 (17.4)

5080 (27.3)

111,933 (17.7)

2142 (27.9)

1970–1974

243,458 (16.5)

4097 (22.0)

112,549 (17.8)

1837 (23.9)

1975–1979

218,052 (14.8)

2428 (13.0)

103,626 (16.4)

1097 (14.3)

1980–1984

216,518 (14.7)

1628 (8.7)

106,187 (16.8)

753 (9.8)

1985–1990

298,769 (20.3)

1049 (5.6)

116,128 (18.4)

374 (4.9)

Primary

226,819 (15.4)

2304 (12.4)

104,799 (16.6)

957 (12.5)

High school

604,802 (41.1)

9435 (50.6)

262,378 (41.6)

3910 (51.0)

Total number
Year of birth

Educational level

College and beyond

379,324 (25.8)

6005 (32.2)

166,447 (26.4)

2508 (32.7)

Unknown

261,365 (17.8)

884 (4.7)

97,612 (15.5)

299 (3.9)

South

342,159 (23.2)

3602 (19.3)

150,946 (23.9)

1514 (19.7)

Middle

825,202 (56.0)

11,293 (60.6)

347,545 (55.1)

4597 (59.9)

North

304,949 (20.7)

3733 (20.0)

132,745 (21.0)

1563 (20.4)

No

1,327,241 (90.1)

14,169 (76.1)

571,236 (90.5)

5870 (76.5)

Yes

145,069 (9.9)

4459 (23.9)

60,000 (9.5)

1804 (23.5)

PYs (%)

PYs (%)

PYs (%)

PYs (%)

No

13,820,488 (95.6)

83,418 (89.3)

6,050,657 (95.9)

34,195 (89.7)

Yes

636,709 (4.4)

10,005 (10.7)

261,787 (4.1)

3932 (10.3)

Region of residency

History of injury

Psychiatric comorbiditiesb

N number, PYs person-years
a
Sibling cohort was restricted to women with at least one identifiable full sister in the population cohort
b
Psychiatric disorder was considered as time-varying, i.e., person-years from the cohort entry if any diagnosis of psychiatric disorders occurred before cohort entry,
or person-years from the date of diagnosis if any diagnosis of psychiatric disorders occurred during the follow-up
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To provide insights into the temporal pattern, for each
PMD patient, we randomly selected 5 women from the
study base who had not yet been diagnosed with PMD
by the patient’s index date (i.e., the matching date); reference women were individually matched to PMD patients by birth year (within a 5-year range) and region of
residency. We then plotted the cumulative incidence
rates and CIs of suicidal behavior and accidents, from
the diagnosis/matching date, using survci package in
STATA. We further estimated HRs of suicidal behavior
and accidents across different time windows, including
within 1 year, >1 to 2 years, and >2 years after PMD
diagnosis, separately.
A diagnosis of PMD may be delayed for years from
symptom onset [35]. We therefore conducted an additional analysis to estimate the risk of injury preceding
diagnosis among PMD patients (i.e., from cohort entry
to the date of diagnosis), compared to women without
PMD. Due to risk of a delay in PMD diagnosis, we also
conducted a sensitivity analysis by excluding persontime preceding the diagnosis of PMD (i.e., from cohort
entry to the date of diagnosis).
To shed light on the impact of psychiatric comorbidities, we performed an analysis stratified by psychiatric
comorbidities by estimating HRs in the presence and absence of psychiatric comorbidities. To identify potential
risk modifiers, we also performed stratified analyses for
any injury by calendar year of birth, educational level, region of residency, and history of injury.
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Data were prepared in SAS statistical software version
9.4 (SAS Institute, Cary, NC) and analyzed in Stata 15.1
(STATA, College Station, TX). The statistical significance was set at the nominal two-sided 5% level.

Results
Characteristics

In total, we identified 18,628 women with a clinical indication of PMD, of which 7674 had identifiable full sisters. The average age at diagnosis was 36 years (standard
deviation 7 years). Compared with the general female
population, women with PMD were older, had higher
educational attainment, and were more likely to have a
history of injury and psychiatric comorbidities (Table 1)
at baseline. Similar patterns were observed in the sibling
analysis. PMD patients identified from the Patient Register were slightly different from those identified from the
Prescribed Drug Register (Supplementary Table S2).
Risk of injury

During the maximal follow-up of 12 years (mean 9.55
years), we identified a total of 22,636 women with injury
due to suicidal behavior (216 in the PMD group), and
315,162 women with injury due to accidents (2191 in
the PMD group) in the population analysis; of these,
9000 women with suicidal behavior (89 in the PMD
group), and 132,900 women with accidents (895 in the
PMD group) were included in the sibling analysis. After
receiving a diagnosis of PMD, the cumulative incidence

Fig. 1 Cumulative incidence rates (CIR) of suicidal behavior and accidents. Each PMD patient was individually matched to 5 individuals without
PMD at the diagnosis/matching date by birth year (within a 5-year range) and region of residency as the reference group
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rate of suicidal behaviors and accidents rapidly increased
over time and reached about 1.6% and 17%, respectively,
by 12 years of follow-up, which were considerably higher
than in the matched reference group (Fig. 1).
Compared to women without PMD, women with
PMD were at increased risk of suicidal behavior (HR
1.65, 95% CI 1.43 to 1.89) and accidents (HR 1.28, 95%
CI 1.23 to 1.34), in the population analysis. The sibling
analysis gave similar estimates for accidents, though
slightly lower estimates for suicidal behavior events with
lower precision. Additional adjustment for psychiatric
comorbidities minimally altered the associations with
any injury and accidents in both population and sibling
analyses. The association with suicidal behavior was considerably attenuated to non-significance in the sibling
analysis (Table 2). For assaults and other undetermined
injury, positive associations were observed in the population analysis but attenuated towards null in the sibling
analysis (supplementary Table S3). We found elevated
risks for all types of accidents among women with PMD
in the population and similar associations in the sibling
analysis (supplementary Table S4).
Sensitivity analyses

Results stayed substantially similar to the main analysis
when (1) adjusting for the number of psychiatric disorders or type-specific psychiatric comorbidities separately
(supplementary Tables S5, S6); (2) adjusting for history
of suicidal behavior when assessing the risk of suicidal
behavior (supplementary Table S7); (3) restricting to
PMD patients who received one or two clinical diagnoses made by specialists, regardless of the prescribed
medications (supplementary Table S8); or (4) excluding
the person-time preceding the diagnosis among PMD
patients (supplementary Table S9).
Women with PMD who were not using antidepressants or oral contraceptives, were at significantly higher
risk of suicidal behavior and accidents, in both population and sibling analyses (supplementary Table S10).
Simulation analysis indicated that the observed associations in the population analysis remained up to the point
where 80% of PMD diagnoses would be false positives
(supplementary Table S11).
Temporal pattern

The higher risk of suicidal behavior and accidents associated with PMD was strong within the first 2 years after
PMD diagnosis, particularly the first year (HR 2.84, 95%
CI 2.29 to 3.52 for suicidal behavior; HR 1.72, 95% CI
1.60 to 1.86 for accidents in the population analysis, Fig.
2). Relative risks declined somewhat by 2 years after
PMD diagnosis (HR 1.43, 95% CI 1.12 to 1.64 for suicidal behavior and HR 1.07, 95% CI 1.01 to 1.14 for accidents in the population analysis). Similar results were
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observed in sibling analysis but not statistically significant for suicidal behavior due to small number of events.
The risk of injury was already somewhat higher for
PMD patients in the period pre-diagnosis (suicidal behavior: HR 1.67, 95% CI 1.50 to 1.86 in the population
analysis; HR 1.43, 95% CI 0.96 to 2.14 in the sibling analysis; and accidents: HR 1.12, 95% CI 1.08 to 1.16 in the
population analysis; HR 1.10, 95% CI 0.99 to 1.23 in the
sibling analysis).
Stratified analysis

In a stratified analysis, an increased risk of accidents was
noted for women with PMD with and without psychiatric comorbidities in the population analysis, with
slightly stronger association for accidents for PMD patients without psychiatric comorbidities (P for interaction=0.007; Table 3). However, this pattern was not
observed in the sibling analysis (P for interaction=0.783).
Comparable associations were observed for suicidal behavior in both population and sibling analyses. An increased risk of any injury was observed for women with
PMD regardless of history of injury. The association was
stronger for PMD with a history of injury in the population analysis, although there was lack of precision in the
sibling analysis. Finally, year of birth, educational level,
and region of residency did not clearly modify the associations with injury risk (supplementary Table S12).

Discussion
In this nationwide cohort study of around 1.5 million
women, we found that women a clinical indication of
PMD had increased risks of injury due to accidents and
suicidal behavior compared with the general female
population, particularly within the first 2 years after
PMD diagnosis. The increased risk was also statistically
significant for accidents when comparing women with
PMD with their full sisters, regardless of psychiatric comorbidities. The association of PMD with risk of suicidal
behavior attenuated to non-significance in the sibling
analysis after controlling for psychiatric comorbidities,
suggesting a considerable contribution of concurrent
psychiatric disorders.
Our findings are supported by a few earlier studies
reporting a positive correlation between PMD and suicidal ideation [12], whereas a positive, independent association with suicidal attempts has only been previously
noted for PMDD [13, 36]. The existing literature is limited to cross-sectional or retrospective case-control
study designs, and therefore not informative as to the
causal direction of the association of PMD with suicidal
behavior. With prospectively collected data on both
PMD and suicide behavior, the present study is the first
to report an increased risk of suicidal behavior among
women with PMD. Although somewhat attenuated and

312,971 (21.4)

Accidents

2,191 (23.2)

216 (2.1)

b

1.32 (1.27–1.38)

2.26 (1.97–2.59)

1.37 (1.31–1.42)

HR (95% CI)

Model 1

<0.01

<0.01

<0.01

P
c

1.28 (1.23–1.34)

1.65 (1.43–1.89)

1.30 (1.25–1.36)

HR (95% CI)

Model 2

<0.01

<0.01

<0.01

P

132,005 (20.7)

8,911 (1.2)

141,677 (22.4)

N (IR)

Reference

Sibling analysis

895 (23.2)

89 (2.1)

973 (25.5)

N (IR)

PMD

a

b

1.29 (1.14–1.46)

1.86 (1.21–2.87)

1.31 (1.16–1.48)

HR (95% CI)

Model 1

<0.01

0.01

<0.01

P

c

1.27 (1.12–1.44)

1.44 (0.87–2.40)

1.28 (1.14–1.45)

HR (95% CI)

Model 2

<0.01

0.16

<0.01

P

N number, IR crude incidence rate per 1000 person-years, HR hazard ratio, CI confidence interval
a
Analyses were stratified on full sister sets
b
HRs were controlled for attained age as the underlying timescale, calendar year of birth (1960–1965, 1966–1970, 1971–1975, 1976–1980, 1981–1985, or 1986–1990), educational level (primary school, high school,
college and beyond, or unknown), region of residence (south, middle, or north of Sweden), and history of injury (yes or no)
c
HRs were additionally adjusted for psychiatric comorbidities (yes or no)

22,420 (1.3)

Suicidal behavior

N (IR)

2,390 (25.6)

N (IR)

336,632 (23.3)

Any injury

PMD

Reference

Population analysis

Table 2 Associations of premenstrual disorders (PMD) with subsequent risk of injury
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Fig. 2 Hazard ratios (HRs) and 95% confidence intervals (CIs) of injury after receiving a diagnosis of premenstrual disorders (PMD). Sibling analysis
was stratified on full sister sets. HRs were controlled for attained age as the underlying timescale and additionally adjusted for calendar year of
birth (1960–1965, 1966–1970, 1971–1975, 1976–1980, 1981–1985, or 1986–1990), educational level (primary school, high school, college and
beyond, or unknown), region of residence (south, middle, or north of Sweden), history of injury (yes or no), and psychiatric comorbidities (yes or
no). Blue dots denote HRs estimated from the population analysis, while red triangles represent HRs estimated from the sibling analysis. N,
number; IR, crude incidence rate per 1000 person-years; HR, hazard ratio; CI, confidence interval

lacking power in our primary analysis, the results from
the sibling analysis lend some support to these findings.
Indeed, psychological distress, a consistent predictor of
suicidal behavior [37], is common among women with
PMD due to the cyclic premenstrual symptoms and

reduced quality of life [9] and may predispose them to
higher risk of suicidal behavior.
No previous study has systematically investigated the
association between PMD and accidents in a populationbased setting. Two small retrospective studies found a

Table 3 Associations of premenstrual disorders (PMD) with subsequent risk of injury, stratified by psychiatric comorbidities
Sibling analysis a

Population analysis
Reference N (IR) PMD N (IR) HR (95% CI)

b

P for interaction Reference N (IR) PMD N (IR) HR (95% CI) b

P for interaction

Any injury
By psychiatric comorbidities
No

306,980 (22.2)

Yes 29,652 (46.6)

1923 (23.1)

1.34 (1.28–1.40)

467 (46.7)

1.17 (1.06–1.28)

70 (0.8)

1.76 (1.34–2.19)

146 (12.3)

1.60 (1.33–1.86)

1821 (21.7)

1.32 (1.26–1.38)

370 (34.5)

1.12 (1.00–1.24)

0.010

130,121 (21.5)

795 (23.2)

1.25 (1.08–1.41)

11,556 (44.1)

178 (45.3)

1.54 (1.01–2.07)

5156 (0.7)

28 (0.7)

1.41 (0.48–2.34)

3755 (11.1)

61 (13.3)

1.50 (0.29–2.70)

122,255 (20.1)

754 (22.0)

1.26 (1.09–1.43)

9750 (33.2)

141 (33.4)

1.37 (0.89–1.84)

0.304

Suicidal behavior
By psychiatric comorbidities
No

12,678 (0.8)

Yes 9742 (11.8)

0.437

0.870

Accidents
By psychiatric comorbidities
No

288,068 (20.7)

Yes 24,903 (34.8)

0.007

0.783

N number, IR crude incidence rate per 1000 person-years, HR hazard ratio, CI confidence interval
a
Analyses were stratified on full sister sets
b
HRs were controlled for attained age as the underlying timescale and additionally adjusted for calendar year of birth (1960–1965, 1966–1970, 1971–1975, 1976–
1980, 1981–1985, or 1986–1990), educational level (primary school, high school, college and beyond, or unknown), region of residence (south, middle, or north of
Sweden), and history of injury (yes or no)
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positive correlation between premenstrual symptoms
and accidents in hospitalized patients and female soccer
players [21, 22]. Our findings therefore add to the knowledge base that, compared to the general population,
women with clinically diagnosed/indicated PMD are at
higher risk of accidents overall (experienced by approximately 17% of PMD patients over the clinical course in
our sample) and for specific types of accidents. This may
be explained by the negative influence of premenstrual
symptoms on energy, concentration, neuromuscular coordination, and perception. It has been documented that
PMD patients have impaired manual dexterity during
the premenstrual phase [38] and poorer concentration
and coordination [39], which might contribute to increased falls and transportation accidents. Moreover,
PMD patients often suffer from emotional problems
(e.g., outbursts of anger and irritation) before menstruation, which might increase their risk of accidents [40].
Yet, further research is needed to understand the underlying mechanisms between PMD and risk for accidents.
Previous studies have shown that psychiatric comorbidities are common among women with PMD. Approximately 40% of cases suffer comorbid depressive
symptoms and 70% suffer comorbid anxiety symptoms
[13], both of which are well-known to be risk factors for
suicide [41]. Indeed, in our study, the additional adjustment for the presence and/or number of psychiatric comorbidities attenuated the observed associations for
suicidal behavior, which is consistent with previous findings [13] and suggest considerable contribution of psychiatric comorbidities to the studied association.
However, psychiatric comorbidities can confound and/or
mediate the studied association. For instance, PMD can
prospectively lead to the development of major depression [42], which results in an episode of suicidal behavior [43]. In this scenario, depression is a mediator to the
effect of PMD on suicidal behavior and adjusting for mediators would lead to conservative results [44]. It is also
possible that depression leads to both the development
of PMD and suicidal behavior, acting as a confounder.
However, we have observed largely comparable associations, although the CIs are wide, among women with
and without psychiatric comorbidities, lending support
to the notion that the observed association may not be
entirely explained by psychiatric comorbidities.
Our study shows that the increased risk of injury, either due to suicidal behavior or accidents, was most
prominent within 2 years after diagnosis. This may reflect the severity of symptoms leading to diagnosis, as it
has been shown that it can take more than 5 years on
average between symptom onset and PMS diagnosis
[35]. Moreover, the increased risk immediately following
a diagnosis of severe illness has been noted for many
diseases and is likely due the increased stress associated
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with living with the disease and/or undergoing intensive
treatment [37]. Future research is needed to understand
patients’ perception of PMD diagnosis and follow-up.
The attenuation of this elevated risk 2 years postdiagnosis may be explained by the efficacy of antidepressants [45, 46] or oral contraceptives [38, 47] treatments
for PMD. Indeed, additional analysis restricted to
women untreated for PMD revealed a robust association
with both suicidal behavior and accidents in both population and sibling analyses. However, it is notable that
risk remained elevated for 12 years after PMD diagnosis.
Additionally, our data indicate that the elevated risk of
injury also precedes PMD diagnosis, which might be due
to a delay in diagnosing women with these conditions
[35].
In addition to the overall elevated risk of injury among
women with PMD, the risk of injury may vary among
PMD women between late luteal phase and symptomfree days. Yet, the chronic and cyclic PMD symptoms
and resulting impairments in interpersonal relationships
and social activities may have a lasting impact on
women with PMD. Indeed, several cross-sectional studies have indicated that PMD are correlated with lower
quality of life in daily lives in both mental and physical
domains [39, 48–50], and a clinical trial has noted impaired quality of life even during symptom-free days
(i.e., in the follicular phase), compared to healthy women
[9]. Moreover, women with PMD commonly have comorbid depression and anxiety [33] resulting in lasting
mental distress beyond the late luteal phase. Our data
indeed indicate that psychiatric comorbidities may at
least partly explain the association between PMD and
suicidal behavior suggesting the impact of PMD may last
beyond the late luteal phase. However, future research is
needed to examine the potentially varying risk of injury
across the menstrual cycle.
Strength and limitations

The major merit of our study is the large-scale
population-based cohort with prospectively collected information on both PMD with clinical indications and injury, which minimizes bias due to selection and
measurement. The sibling analysis further allows us to
rigorously control for familial factors shared between full
sisters, such as genetic factors and familial environment
during childhood. However, our study also has limitations. First, the clinical diagnoses of PMD have not been
validated in the Swedish Patient Register. The healthcare
guidelines in most regions in Sweden, for instance the
one in Stockholm [24], have specified that “the diagnosis
must be confirmed by the woman making daily prospective evaluation of symptoms for at least two consecutive menstrual cycles”. The clinical guidelines are
often well followed in the state-funded public healthcare
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system in Sweden. Furthermore, the quality for the diagnoses in the Patient Register has been considered fairly
high in general [51] and for a range of psychiatric disorders [52–55] and OB/GYN diseases [23, 56]. Moreover,
our sensitivity analysis limited to PMD with two consecutive diagnoses 28 days apart have showed highly
similar results to the primary population analysis, although we lacked power in the sibling analysis. In
addition, our simulation analysis indicates that the observed association between PMD and injury in the population analysis would remain unless >80% of PMD
diagnoses were incorrect. In addition, PMD identified
only via treatment indication from the Prescribed Drug
Register, and not clinical diagnosis, might represent less
severe PMD. However, our sensitivity analysis restricted
to PMD diagnosed in specialist care (as obtained from
the Patient Register) yielded very similar results. Second,
it might take years and many healthcare visits from the
time of symptom onset to the receipt of a clinical diagnosis of PMD [35]. Thus, the date of PMD diagnosis in
our data may not reflect either the timing of symptom
onset or first clinical diagnosis, particularly for women
who diagnosed before 2001 (i.e., when the Patient Register started to collect specialists-based outpatient diagnoses). This is supported by the higher proportion of PMD
women with history of injury at cohort entry as well as
the increased risk of injury before the date of diagnosis
reported during the observation period. However, a sensitivity analysis excluding person-time preceding diagnosis among PMD patients yielded highly similar results.
Third, the identified PMD individuals likely represent a
patient group with most severe PMD symptomology,
particularly those who felt obliged to seek help from
healthcare and those who had more severe psychiatric
comorbidities. Our findings may therefore not be generalized to individuals with milder premenstrual symptoms. Fourth, we lacked information on some potential
confounding factors, e.g., childhood abuse [57, 58],
smoking [59, 60], and had considerable missing data on
educational level. However, we observed robust associations between PMD and accidents in the sibling analysis,
which controls for factors shared between full sisters.
Lastly, it is possible that women with other patterns of
menstruation-related symptoms, such as premenstrual
exacerbation of a pre-existing psychiatric disorder, are
also at increased risk of injury. Future research is therefore needed for other menstrual cycle-related disorders
[61].

Conclusions
Our findings suggest that women with a clinical indication of PMD are at increased risks of injury, particularly
due to accidents. Health professionals may consider
higher vigilance for such risk in women with clinically
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diagnosed PMD, particularly within the first 2 years after
diagnosis. Future research is needed to understand the
risk of injury among women with milder premenstrual
symptoms.
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